Comparison of TP53-mutated to TP53 wild-type and multihit to monoallelic TP53-mutated cases
| . | TP53-mutated (n = 247) . | TP53 wild-type (n = 52) . | P . | TP53 biallelic (n = 180) . | TP53 monoallelic (n = 67) . | P . |
|---|---|---|---|---|---|---|
| Age | 70 (21-91) | 68 (1-87) | .06 | 70 (30-91) | 70 (22-87) | .93 |
| Gender, M:F | 124:114 | 26:26 | 98:82 | 35:32 | .0009 | |
| WHO subtypes | ||||||
| AML | 113 (46%) | 31 (59%) | 94 (52%) | 19 (28%) | ||
| MDS-SLD | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | ||
| MDS-MLD | 32 (13%) | 6 (12%) | 19 (11%) | 13 (19%) | ||
| MDS–RS-SLD | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| MDS–RS-MLD | 10 (4%) | 1 (2%) | 10 (6%) | 0 (0%) | ||
| MDS-U | 1 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | ||
| MDS-EB1 | 37 (15%) | 4 (8%) | 21 (12%) | 16 (24%) | ||
| MDS-EB2 | 54 (22%) | 9 (17%) | 35 (19%) | 19 (28%) | ||
| Monosomal karyotype | 168 (69%) | 13 (25%) | <.0001 | 130 (72%) | 38 (59%) | .06 |
| Blood counts (median, range) | ||||||
| ANC | 1.0 (0-58.7) | 0.9 (0-25.4) | .55 | 1.0 (0-13) | 1.0 (0.01-6.7) | .47 |
| HGB | 8.5 (3.8-12.9) | 9.0 (4.9-13.7) | .004 | 8.4 (3.8-12.9) | 9 (4.0-12.5) | .12 |
| WBC | 3.0 (0.6-88.2) | 3.2 (0.1-281.0) | .28 | 3.2(0.6-88) | 2.6 (0.6-88) | .035 |
| Platelets | 50 (3-464) | 54 (5-347) | .44 | 49 (3-464) | 52 (13-225) | .5 |
| PB blasts | 1 (0-90) | 4 (0-97) | .17 | 1 (0-90) | 1 (0-45) | .024 |
| BM features | ||||||
| Cellularity | 70 (25-100) | 60 (20-100) | .14 | 70 (10-100) | 65 (10-100) | .036 |
| Blast % | 15 (0-95) | 35 (1-95) | .02 | 19 (0-95) | 12 (0-95) | .015 |
| . | TP53-mutated (n = 247) . | TP53 wild-type (n = 52) . | P . | TP53 biallelic (n = 180) . | TP53 monoallelic (n = 67) . | P . |
|---|---|---|---|---|---|---|
| Age | 70 (21-91) | 68 (1-87) | .06 | 70 (30-91) | 70 (22-87) | .93 |
| Gender, M:F | 124:114 | 26:26 | 98:82 | 35:32 | .0009 | |
| WHO subtypes | ||||||
| AML | 113 (46%) | 31 (59%) | 94 (52%) | 19 (28%) | ||
| MDS-SLD | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | ||
| MDS-MLD | 32 (13%) | 6 (12%) | 19 (11%) | 13 (19%) | ||
| MDS–RS-SLD | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| MDS–RS-MLD | 10 (4%) | 1 (2%) | 10 (6%) | 0 (0%) | ||
| MDS-U | 1 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | ||
| MDS-EB1 | 37 (15%) | 4 (8%) | 21 (12%) | 16 (24%) | ||
| MDS-EB2 | 54 (22%) | 9 (17%) | 35 (19%) | 19 (28%) | ||
| Monosomal karyotype | 168 (69%) | 13 (25%) | <.0001 | 130 (72%) | 38 (59%) | .06 |
| Blood counts (median, range) | ||||||
| ANC | 1.0 (0-58.7) | 0.9 (0-25.4) | .55 | 1.0 (0-13) | 1.0 (0.01-6.7) | .47 |
| HGB | 8.5 (3.8-12.9) | 9.0 (4.9-13.7) | .004 | 8.4 (3.8-12.9) | 9 (4.0-12.5) | .12 |
| WBC | 3.0 (0.6-88.2) | 3.2 (0.1-281.0) | .28 | 3.2(0.6-88) | 2.6 (0.6-88) | .035 |
| Platelets | 50 (3-464) | 54 (5-347) | .44 | 49 (3-464) | 52 (13-225) | .5 |
| PB blasts | 1 (0-90) | 4 (0-97) | .17 | 1 (0-90) | 1 (0-45) | .024 |
| BM features | ||||||
| Cellularity | 70 (25-100) | 60 (20-100) | .14 | 70 (10-100) | 65 (10-100) | .036 |
| Blast % | 15 (0-95) | 35 (1-95) | .02 | 19 (0-95) | 12 (0-95) | .015 |
ANC, Absolute neutrophil count; HGB, Hemoglobin; MDS-EB1, Myelodysplastic syndrome with excess blasts-1; MDS-EB2, Myelodysplastic syndrome with excess blasts-2; MDS–RS-MLD, Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia; MDS–RS-SLD, Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia; MDS-U, Myelodysplastic syndrome, unclassifiable; PB, Peripheral blood; WBC, White blood cell count.